Please assess the completion status of the following clinical trial:

Trial Title: Protease Inhibitors and Combined Oral Contraceptive Pharmacokinetics and Pharmacodynamics

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV positive~* Female~* Age 18-45~* Using any of the following medication regimens: no ARV medication, entry inhibitors, nucleoside reverse transcriptase inhibitors (NRTIs), integrase inhibitors, and CCR5 agonists. Acceptable NRTI combinations include zidovudine (ZDV), lamivudine (3TC), emtricitabine (FTC), didanosine (ddl), stavudine (d4T), abacavir (ABC), and tenofovir disoproxil fumarate (TDF)~* Ovulatory (mid-luteal progesterone \>3ng/dL)~* Not planning to conceive during the study period~* Willing to abstain from grapefruit products~* If taking ritonavir, willing to use alternate non-hormonal contraception~* BMI \< or = 40~* Able to consent in English or Spanish~* No change in medication regimen for at least 21 days prior to study entry and no planned change during the study period~* CD4 \> or =200, and/or not considered profoundly immuncompromised by primary HIV provider~Exclusion Criteria:~* Using on the combination of ZDV at d4T~* Platelets \<50,000~* AST or ALT \> twice upper limit of normal~* Bilirubin \> twice upper limit of normal~* Use of other CYP3A4 inducing or inhibiting medications~* Pregnant or breastfeeding in last 30 days~* Use of DepoProvera in last 180 days~* Use of any other hormonal contraception in last 30 days~* Undiagnosed vaginal bleeding or invasive cancer of the reproductive tract~  -\>50% change in tobacco use in the last month~* Initiation or titration of methadone therapy in the last month~* Uncontrolled thyroid disease~* Contraindication to estrogen use~* Inability to comply with study protocol

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Ritonavir (Type: EXPERIMENTAL): Participants taking antiretroviral regimens including ritonavir-boosted protease inhibitors will take a combined oral contraceptive containing 150mcg levonorgestrel and 30mcg ethinyl estradiol for 21 days.
- Control (Type: ACTIVE_COMPARATOR): Participants taking antiretroviral regimens known not to interact with oral contraceptives will take a combined oral contraceptive containing 150mcg levonorgestrel and 30mcg ethinyl estradiol for 21 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).